Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Shibo Jiang, Maria Elena Bottazzi, Lanying Du, Sara Lustigman, Chien-Te Tseng, Elena Curti, Kathryn Jones, Bin Zhan, Peter J. Hotez

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.

Original languageEnglish (US)
Pages (from-to)1405-1413
Number of pages9
JournalExpert Review of Vaccines
Volume11
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Severe Acute Respiratory Syndrome
Coronavirus
Protein Binding
Vaccines
Oral Poliovirus Vaccine
Subunit Vaccines
Protein S
Neutralizing Antibodies

Keywords

  • receptor-binding domain
  • recombinant vaccine
  • SARS
  • severe acute respiratory syndrome
  • spike (S) protein

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. / Jiang, Shibo; Bottazzi, Maria Elena; Du, Lanying; Lustigman, Sara; Tseng, Chien-Te; Curti, Elena; Jones, Kathryn; Zhan, Bin; Hotez, Peter J.

In: Expert Review of Vaccines, Vol. 11, No. 12, 12.2012, p. 1405-1413.

Research output: Contribution to journalArticle

Jiang, Shibo ; Bottazzi, Maria Elena ; Du, Lanying ; Lustigman, Sara ; Tseng, Chien-Te ; Curti, Elena ; Jones, Kathryn ; Zhan, Bin ; Hotez, Peter J. / Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. In: Expert Review of Vaccines. 2012 ; Vol. 11, No. 12. pp. 1405-1413.
@article{fba517a5be4e4104a25c12cf2045238f,
title = "Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome",
abstract = "A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.",
keywords = "receptor-binding domain, recombinant vaccine, SARS, severe acute respiratory syndrome, spike (S) protein",
author = "Shibo Jiang and Bottazzi, {Maria Elena} and Lanying Du and Sara Lustigman and Chien-Te Tseng and Elena Curti and Kathryn Jones and Bin Zhan and Hotez, {Peter J.}",
year = "2012",
month = "12",
doi = "10.1586/erv.12.126",
language = "English (US)",
volume = "11",
pages = "1405--1413",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

AU - Jiang, Shibo

AU - Bottazzi, Maria Elena

AU - Du, Lanying

AU - Lustigman, Sara

AU - Tseng, Chien-Te

AU - Curti, Elena

AU - Jones, Kathryn

AU - Zhan, Bin

AU - Hotez, Peter J.

PY - 2012/12

Y1 - 2012/12

N2 - A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.

AB - A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.

KW - receptor-binding domain

KW - recombinant vaccine

KW - SARS

KW - severe acute respiratory syndrome

KW - spike (S) protein

UR - http://www.scopus.com/inward/record.url?scp=84871559431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871559431&partnerID=8YFLogxK

U2 - 10.1586/erv.12.126

DO - 10.1586/erv.12.126

M3 - Article

VL - 11

SP - 1405

EP - 1413

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 12

ER -